Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2015

01-02-2015 | Laboratory Investigation

MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma

Authors: Shoudan Zhang, Qigui Qi

Published in: Journal of Neuro-Oncology | Issue 3/2015

Login to get access

Abstract

Glioblastomas (GBMs) are the highest grade of primary brain tumors with astrocytic similarity and are characterized dispersal of tumor cell. Metastasis suppressor 1 (MTSS1) play an important role in cancer metastasis. Recent studies indicating that MTSS1 as a potential tumor suppressor and its reduced expression associated with poor prognosis in many cancer types. However, the relationship with the prognosis of patients and the molecular mechanism of MTSS1 renders a tumor suppressor effect in GBM is unknown. Here, we showed that low MTSS1 gene expression is associated with poor outcomes in patients with GBM. Overexpression of MTSS1 in U-87 MG cells exhibited inhibited glioma cell growth, colony formation, migration and invasion. Mechanistically, we found that high MTSS1 expression in U-87 MG reduced expression of CTTN. These results implicate that the role of MTSS1 suppresses cell migration and invasion by inhibiting expression of CTTN and as a prognosis biomarker in GBM.
Literature
1.
Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA et al (2014) Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 156(3):603–616PubMedCentralPubMedCrossRef
2.
Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J (2013) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10(1):14–26PubMedCrossRef
3.
4.
Utikal J, Gratchev A, Muller-Molinet I, Oerther S, Kzhyshkowska J, Arens N et al (2006) The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation. Int J Cancer 119(10):2287–2293PubMedCrossRef
5.
Parr C, Jiang WG (2009) Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 45(9):1673–1683PubMedCrossRef
6.
Huang XY, Huang ZL, Xu YH, Huang XY, Zhou J, Ye SL et al (2010) Effects of MIM-B gene on invasive and metastatic potentials of human hepatocellular carcinoma MHCC97H cells. Zhonghua Gan Zang Bing Za Zhi 18(12):915–919PubMed
7.
Ma S, Guan XY, Lee TK, Chan KW (2007) Clinicopathological significance of missing in metastasis B expression in hepatocellular carcinoma. Hum Pathol 38(8):1201–1206PubMedCrossRef
8.
Bompard G, Sharp SJ, Freiss G, Machesky LM (2005) Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci 118(Pt 22):5393–5403PubMedCrossRef
9.
Callahan CA, Ofstad T, Horng L, Wang JK, Zhen HH, Coulombe PA et al (2004) MIM/BEG4, a Sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev 18(22):2724–2729PubMedCentralPubMedCrossRef
10.
Wang D, Xu MR, Wang T, Li T, Zhu J (2011) MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg 15(7):1205–1212PubMedCrossRef
11.
12.
Lin J, Liu J, Wang Y, Zhu J, Zhou K, Smith N, Zhan X (2005) Differential regulation of cortactin and NWASP- mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene 24(12):2059–2066
13.
Wu H, Reynolds AB, Kanner SB, Vines RR, Parsons JT (1991) Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 11(10):5113–5124PubMedCentralPubMed
14.
Buday L, Downward J (2007) Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta 1775(2):263–273PubMed
15.
16.
17.
Mezi S, Todi L, Orsi E, Angeloni A, Mancini P (2012) Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells. Int J Oncol 41(6):2128–2138PubMed
18.
Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, Nozawa Y et al (2012) Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol 19(1):71–79PubMedCrossRef
19.
Hirakawa H, Shibata K, Nakayama T (2009) Localization of cortactin is associated with colorectal cancer development. Int J Oncol 35(6):1271–1276PubMedCrossRef
20.
Hashimoto A, Hashimoto S, Ando R, Noda K, Ogawa E, Kotani H et al (2011) GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS ONE 6(8):e23359PubMedCentralPubMedCrossRef
21.
Cen G, Ding HH, Liu B, Wu WD (2014) FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration. Tumour Biol 35(9):8633–82014PubMedCrossRef
22.
Xu XZ, Garcia MV, Li TY, Khor LY, Gajapathy RS, Spittle C et al (2010) Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol 23(2):187–196PubMedCentralPubMedCrossRef
23.
Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X et al (2012) MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene 31(18):2298–2308PubMedCrossRef
24.
25.
Li J, Lu X (2013) The emerging roles of 3′ untranslated regions in cancer. Cancer Lett 337(1):22–25PubMedCrossRef
Metadata
Title
MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma
Authors
Shoudan Zhang
Qigui Qi
Publication date
01-02-2015
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1656-2

Other articles of this Issue 3/2015

Journal of Neuro-Oncology 3/2015 Go to the issue

Laboratory Investigation

Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM

Laboratory Investigation

Tissue thioredoxin reductase-1 expression in astrocytomas of different grades

Clinical Study

A comparative study of intraventricular central neurocytomas and extraventricular neurocytomas

Laboratory Investigation

Periostin: a novel prognostic predictor for meningiomas

Clinical Study

Deficiency of very large G-protein-coupled receptor-1 is a risk factor of tumor-related epilepsy: a whole transcriptome sequencing analysis

Clinical Study

Health related quality of life (HRQOL) in long-term survivors of pediatric low grade gliomas (LGGs)